Tiziana Life Sciences (TLSA) Enterprise Value (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Enterprise Value for 9 consecutive years, with -$4.0 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value fell 7.68% year-over-year to -$4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.0 million (down 7.68% YoY) and the FY2025 annual result came in at -$4.0 million, down 7.68% from the prior year.
• Enterprise Value grew to -$4.0 million in Q4 2025 per TLSA's latest filing, from -$7.3 million in the prior quarter.
• Over the last five years, Enterprise Value for TLSA reached as high as $455000.0 in Q2 2024 and fell as low as -$54.0 million in Q2 2021.
• A 5-year average of -$16.4 million and a median of -$7.0 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 106.81% — and 2025, when it tumbled 1693.63%.
• Year by year, Enterprise Value stood at -$42.2 million in 2021, then surged by 54.98% to -$19.0 million in 2022, then jumped by 95.89% to -$781000.0 in 2023, then slumped by 376.82% to -$3.7 million in 2024, then fell by 7.68% to -$4.0 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$4.0 million, -$7.3 million, and -$3.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.